Molecular Pharmagroup

Executive Summary

Molecular Pharmagroup is a private, FDA-registered 503B outsourcing facility based in San Diego, specializing in the sterile compounding and bulk manufacturing of generic drugs, particularly those on the FDA Drug Shortage list. Founded in 2018, the company operates under cGMP and adheres to USP 797 and USP 800 standards, serving hospitals, medical groups, and independent practitioners. With persistent drug shortages in the U.S., the company addresses a critical need by providing reliable, high-quality compounded medications. Its state-of-the-art facility and compliance focus position it well for steady demand from healthcare providers seeking to mitigate supply disruptions. As a private entity, financial details are undisclosed, but the niche market and essential nature of its products suggest a stable revenue base and potential for growth as shortages persist.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval for New Product from Shortage List60% success
• Q4 2026Expansion of Facility or Capacity50% success
• Q2 2026Major Hospital Group Contract Win65% success